Chagas Disease Treatment Market Size, Share & Trends | Industry Growth

 

Chagas disease can be an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as'the kissing bugs '. Moreover, the illness may be transferred through other means such as for instance blood transfusion, organ transplantation, along with congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as for instance Europe and North America, due to migration of individuals from Latin America to others countries. For example, according a study published in National Center for Biotechnology Information (NCBI), in 2015, 4.2% of Latin American residing in European countries were chronically affected with Chagas disease.

Key players operating in the Chagas Disease Treatment market include Nortec Quimica SA, Bayer AG, Laboratorio Elea Phoenix SA, Maprimed S.A., and Laboratório Farmacêutico de Pernambuco S/A.Diagnosis of Chagas disease is done by serological methods, parasitological methods, and molecular method. Parasitological methods includes identification of trypomastigotes in blood by microscopy. Polymerase chain reaction (PCR) is a trusted molecular diagnosis method, since it is a good alternative tool for detection and shows high array of efficiency. Serological method is mainly utilized in the detection of Trypanosoma cruzi antibodies in blood donors, diagnosis of infected people and for epidemic studies.

Benznidazole is a vital antiparasitic drug used for the treatment of Chagas disease. In April 2018, Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT) approved Laboratorio Elea Phoenix SA's drug benznidazole for pediatric indication used for the treatment of Chagas disease. Currently, Argentina has the greatest number of people struggling with Chagas disease. For example, according to data published by Mundo Sano (Nongovernmental foundation in Argentina), in 2017, around 7,300,000 people were confronted with Chagas disease and about 1,600,000 were infected, in Argentina. Hence, approval of novel drugs is likely to fuel the market growth in the near future. Such approval of Chagas disease treatment drugs is expected to enhance growth of Chagas disease treatment market in the near future.

See Full Report@ https://bit.ly/3yqORwE